Compare Stocks → The Department of Defense Has a New Drone Contractor (From The Tomorrow Investor) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:GRINASDAQ:HSTONASDAQ:NBSENASDAQ:PBLA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGRIGRI Bio0.42+5.3%0.630.38▼53.13$1.34M-1.55548,863 shs1,279 shsHSTOHistogen$0.16+6.7%$0.37$0.05▼$1.05$683K0.9119,980 shs424 shsNBSENeuBase Therapeutics$0.40-2.4%$0.62$0.36▼$4.80$1.50M0.81196,004 shs37,318 shsPBLAPanbela Therapeutics$0.38-7.3%$0.63$0.35▼$300.00$1.33M1.55525,498 shs11,969 shs7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGRIGRI Bio-4.34%-6.88%-23.12%-66.75%-99.15%HSTOHistogen+6.67%-54.43%-68.00%-52.94%-80.68%NBSENeuBase Therapeutics-2.46%-5.21%-0.07%-41.94%-89.46%PBLAPanbela Therapeutics-6.85%-11.40%-33.51%-67.16%-99.87%The Department of Defense Has a New Drone Contractor (Ad)The Department of Defense just granted a major advantage to a small UAV provider. Since 1998, this Nasdaq-listed company has been supplying drones for civilian, enterprise, and military purposes.Click here to see how to investMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGRIGRI BioN/AN/AN/AN/AN/AN/AN/AN/AHSTOHistogenN/AN/AN/AN/AN/AN/AN/AN/ANBSENeuBase TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/APBLAPanbela Therapeutics0.6677 of 5 stars3.50.00.00.00.00.00.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGRIGRI BioN/AN/AN/AN/AHSTOHistogenN/AN/AN/AN/ANBSENeuBase TherapeuticsN/AN/AN/AN/APBLAPanbela Therapeutics3.00Buy$500.00131,133.60% UpsideCurrent Analyst RatingsLatest HSTO, PBLA, GRI, and NBSE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/27/2024PBLAPanbela TherapeuticsRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 5/8/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGRIGRI BioN/AN/AN/AN/A0.40 per shareN/AHSTOHistogen$3.77M0.18N/AN/A$3.13 per share0.05NBSENeuBase TherapeuticsN/AN/AN/AN/A$11.04 per shareN/APBLAPanbela TherapeuticsN/AN/AN/AN/A($18.37) per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGRIGRI Bio-$13.04M-81.48N/A∞N/AN/A-795.54%-345.37%5/20/2024 (Estimated)HSTOHistogen-$10.62M-$2.81N/A∞N/A-65,142.11%-136.13%-90.87%N/ANBSENeuBase Therapeutics-$4.37M-$7.70N/A∞N/AN/A-99.74%-60.13%5/9/2024 (Estimated)PBLAPanbela Therapeutics-$25.26M-$669.09N/AN/AN/AN/A-70,194.55%-172.92%N/ALatest HSTO, PBLA, GRI, and NBSE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/26/2024Q4 2023PBLAPanbela Therapeutics-$24.34-$65.90-$41.56-$65.90N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGRIGRI BioN/AN/AN/AN/AN/AHSTOHistogenN/AN/AN/AN/AN/ANBSENeuBase TherapeuticsN/AN/AN/AN/AN/APBLAPanbela TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGRIGRI BioN/A1.091.09HSTOHistogenN/A4.054.05NBSENeuBase TherapeuticsN/A2.872.87PBLAPanbela TherapeuticsN/A0.250.25OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGRIGRI Bio33.95%HSTOHistogenN/ANBSENeuBase Therapeutics12.37%PBLAPanbela Therapeutics4.37%Insider OwnershipCompanyInsider OwnershipGRIGRI Bio16.82%HSTOHistogen3.30%NBSENeuBase Therapeutics7.90%PBLAPanbela Therapeutics0.01%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableGRIGRI Bio43.20 million2.66 millionNot OptionableHSTOHistogen74.27 million4.13 millionNot OptionableNBSENeuBase Therapeutics373.75 million3.46 millionNot OptionablePBLAPanbela Therapeutics73.48 million3.48 millionNot OptionableHSTO, PBLA, GRI, and NBSE HeadlinesSourceHeadlinePanbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and Sulindacfinance.yahoo.com - May 6 at 7:46 PMPanbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and Sulindacglobenewswire.com - May 6 at 8:00 AMPanbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024globenewswire.com - May 1 at 4:15 PMAcceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease Weekglobenewswire.com - April 30 at 8:00 AMPanbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025globenewswire.com - April 22 at 8:00 AMPanbela Applies to List on CBOEmarketwatch.com - April 18 at 6:11 PMPanbela Announces Poster Presentation at American Association for Cancer Research:globenewswire.com - April 18 at 8:00 AMPanbela Therapeutics, Inc.: Panbela Announces Transfer to OTCQB Marketfinanznachrichten.de - April 17 at 9:49 AMPanbela Announces Transfer to OTCQB Marketfinance.yahoo.com - April 16 at 7:24 PMRecap: Panbela Therapeutics Q4 Earningsbenzinga.com - March 28 at 7:34 PMPanbela Therapeutics, Inc. (PBLA) Q4 2023 Earnings Call Transcriptseekingalpha.com - March 28 at 2:34 PMPanbela Therapeutics, Inc. (NASDAQ:PBLA) Q4 2023 Earnings Call Transcriptmsn.com - March 27 at 3:10 PMPanbela Therapeutics, Inc.: Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Resultsfinanznachrichten.de - March 27 at 10:09 AMPanbela Provides Business Update and Reports Q4 and FY 2024 Financial Resultsglobenewswire.com - March 26 at 4:10 PMEarnings Preview: Panbela Therapeuticsbenzinga.com - March 26 at 1:12 AMPBLA Panbela Therapeutics, Inc.seekingalpha.com - March 22 at 11:01 PMPanbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024globenewswire.com - March 12 at 4:15 PMTop 4 Health Care Stocks That Are Preparing To Pump This Monthmsn.com - February 23 at 11:40 PMTop 4 Health Care Stocks That Are Preparing To Pump This Month - ProSomnus (NASDAQ:OSA), GRI Bio (NASDAQ:GRI)benzinga.com - February 23 at 7:50 AMPanbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirementsfinance.yahoo.com - February 15 at 11:37 AMPanbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirementsglobenewswire.com - February 15 at 8:00 AM10% Owner GOLDMAN SACHS GROUP INC sale 72,874 shares of Panbela Therapeutics Inc. [PBLA]knoxdaily.com - February 1 at 8:01 PMPanbela Announces Closing of Approximately $9.0 Million Public Offeringfinance.yahoo.com - February 1 at 9:59 AMPanbela Therapeutics Inc (PBLA)investing.com - January 31 at 8:53 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Stocks Leading the U.S. Agriculture ComebackApril 26, 2024 10:10 AMView 3 Stocks Leading the U.S. Agriculture ComebackHow to Use Put Debit Spreads to Profit From Falling Stocks April 26, 2024 9:30 AMView How to Use Put Debit Spreads to Profit From Falling Stocks The Meteoric Rise of Chipotle Mexican Grill Stock is Not OverApril 29, 2024 9:00 AMView The Meteoric Rise of Chipotle Mexican Grill Stock is Not Over5 Trends You Need to Know This QuarterApril 13, 2024 9:16 AMView 5 Trends You Need to Know This QuarterAnalysts Agree, This Could Be Tyson Stock’s Comeback YearApril 23, 2024 6:05 AMView Analysts Agree, This Could Be Tyson Stock’s Comeback YearAll Headlines Company DescriptionsGRI BioNASDAQ:GRIGRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.HistogenNASDAQ:HSTOHistogen Inc., a clinical-stage therapeutics company, focuses on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body's natural process to restore immune function. The company's product candidates include emricasan for the treatment of acute bacterial skin and skin structure infections, as well as other infectious diseases. Its preclinical product candidates include CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of various inflammatory diseases. Histogen Inc. was founded in 2007 and is based in San Diego, California. On April 18, 2024, Histogen Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of California.NeuBase TherapeuticsNASDAQ:NBSENeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.Panbela TherapeuticsNASDAQ:PBLAPanbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.